Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Boehringer Ingelheim
Express Scripts
Harvard Business School
Johnson and Johnson

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR HEPARIN CALCIUM


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Heparin Calcium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000472 ↗ Thrombolysis in Myocardial Ischemia Trial (TIMI III) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1989-04-01 The Thrombolysis in Myocardial Ischemia Trial (TIMI III) focused on unstable angina and non-Q-wave myocardial infarction. The trial was designed to determine by coronary arteriography the incidence of coronary thrombi in these conditions and the response of these thrombi to tissue-type plasminogen activator (t-PA) in TIMI IIIA and the effects of thrombolytic therapy and of an early invasive strategy on clinical outcome in TIMI IIIB. There was also a registry with two components. A roster enumerated all patients with unstable angina or non-Q-wave myocardial infarction enrolled at cooperating hospitals. From the roster, a study population of 1,893 subjects was selected and followed prospectively for the year to determine incidence of death or myocardial infarction.
NCT00000473 ↗ Do Fish Oils Prevent Restenosis Post-Coronary Angioplasty? Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1989-07-01 To determine whether a dietary supplement of n-3 polyunsaturated fatty acids (PUFAs) derived from fish oil would decrease the restenosis rate in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
NCT00004786 ↗ Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed University of Pittsburgh Phase 3 1995-12-01 OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis.
NCT00004786 ↗ Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed National Center for Research Resources (NCRR) Phase 3 1995-12-01 OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis.
NCT00212043 ↗ Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma Completed Eli Lilly and Company Phase 2 2000-07-01 Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer
NCT00212043 ↗ Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma Completed National University Hospital, Singapore Phase 2 2000-07-01 Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Heparin Calcium

Condition Name

Condition Name for Heparin Calcium
Intervention Trials
Cardiovascular Diseases 2
Anticoagulant Toxicity 2
Metastatic Cancer 2
Coronary Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Heparin Calcium
Intervention Trials
Ischemia 3
Kidney Diseases 3
Cardiovascular Diseases 3
Proteinuria 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Heparin Calcium

Trials by Country

Trials by Country for Heparin Calcium
Location Trials
Italy 9
Spain 9
United States 5
Brazil 2
China 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Heparin Calcium
Location Trials
Alabama 1
Virginia 1
Pennsylvania 1
Tennessee 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Heparin Calcium

Clinical Trial Phase

Clinical Trial Phase for Heparin Calcium
Clinical Trial Phase Trials
Phase 4 5
Phase 3 9
Phase 2/Phase 3 1
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Heparin Calcium
Clinical Trial Phase Trials
Completed 17
Recruiting 4
Unknown status 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Heparin Calcium

Sponsor Name

Sponsor Name for Heparin Calcium
Sponsor Trials
University of Pittsburgh 2
National University Hospital, Singapore 2
National Heart, Lung, and Blood Institute (NHLBI) 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Heparin Calcium
Sponsor Trials
Other 39
Industry 4
NIH 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Moodys
Merck
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.